MaaT Pharma: Key Phase 3 Results Unveiled at EBMT Congress 2026
MaaT Pharma announces the presentation of clinical data related to its therapeutic portfolio at the 2026 Annual EBMT Congress, to be held from March 22 to 25 in Madrid. The biotechnology company will focus on its hemato-oncology programs, particularly MaaT013, which is currently under regulatory review by the European Medicines Agency following the submission of a Marketing Authorization Application in June 2025.
Keynote Presentation on Final Phase 3 ARES Trial Results
MaaT Pharma will deliver an oral presentation during the presidential plenary session, focusing on the final results of the Phase 3 ARES trial, which assesses MaaT013 in acute graft-versus-host disease with gastrointestinal involvement. Scheduled for Monday, March 23 at 5:33 PM, the presentation will particularly detail overall survival data. The company will supplement this presentation with three posters: the CHRONOS study, a multicenter retrospective cohort describing real-life data in third-line treatment of gastrointestinal aGvHD; the PHOEBUS trial, a Phase 2b program evaluating MaaT033 to improve survival following allogeneic hematopoietic stem cell transplantation; and the THRASSA study, an open multicenter trial conducted in children and adolescents assessing MaaT013 in patients with gastrointestinal aGvHD who are refractory or intolerant to ruxolitinib.
Strengthening Position in Hemato-Oncology at EBMT 2026
MaaT Pharma's scientific presence at the EBMT 2026 Congress allows the company to strengthen its position in hemato-oncology and throughout the continuum of care related to allogeneic hematopoietic stem cell transplantation, as well as its commitment to improving patient management. Clinigen, a strategic commercial partner of MaaT Pharma, will organize a symposium dedicated to the management of acute GvHD on Sunday, March 22 from 12:30 PM to 2:00 PM CET. Clinigen is responsible for managing the compassionate access program for MaaT013 and its potential commercialization in Europe, subject to approval by the European Medicines Agency.
